BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, ...

Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program -HUNTSVILLE, AL, ...

Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug ...

The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial ( NCT07285070) in ...

Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim ...

MicuRx Pharmaceuticals, Inc. ('MicuRx'), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced ...

The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1 +, a DNA plasmid vaccine, in patients with advanced melanoma, scheduled to commence ...

BOSTON, Mass, April 01, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today ...

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...

NextCure (NXTC) announced that the U.S. Food and Drug Administration, FDA, accepted an Investigational New Drug, IND, application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4 ...

Silo Pharma, Inc. announced plans to submit an investigational new drug (IND) application for SPC-15, a novel intranasal treatment for Post-Traumatic Stress Disorder (PTSD), by the end of 2025, ...